|
1
|
Castellanos JA, Merchant NB and
Nagathihalli NS: Emerging targets in pancreatic cancer:
Epithelial-mesenchymal transition and cancer stem cells. Onco
Targets Ther. 6:1261–1267. 2013.PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ouaïssi M, Cabral S, Tavares J, da Silva
AC, Mathieu Daude F, Mas E, Bernard J, Sastre B, Lombardo D and
Ouaissi A: Histone deacetylase (HDAC) encoding gene expression in
pancreatic cancer cell lines and cell sensitivity to HDAC
inhibitors. Cancer Biol Ther. 7:523–531. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Donadelli M, Costanzo C, Beghelli S,
Scupoli MT, Dandrea M, Bonora A, Piacentini P, Budillon A, Caraglia
M, Scarpa A and Palmieri M: Synergistic inhibition of pancreatic
adenocarcinoma cell growth by trichostatin A and gemcitabine.
Biochim Biophys Acta. 1773:1095–1106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu W, Li J, Wu S, Li S, Le L, Su X, Qiu
P, Hu H and Yan G: Triptolide cooperates with Cisplatin to induce
apoptosis in gemcitabine-resistant pancreatic cancer. Pancreas.
41:1029–1038. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim DH, Kim M and Kwon HJ: Histone
deacetylase in carcinogenesis and its inhibitors as anti-cancer
agents. J Biochem Mol Biol. 36:110–119. 2003.PubMed/NCBI
|
|
7
|
Zhang X, Jiang SJ, Shang B and Jiang HJ:
Effects of histone deacetylase inhibitor trichostatin A combined
with cisplatin on apoptosis of A549 cell line. Thorac Cancer.
6:202–208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang B, Zou Q, Sun M, Chen J, Wang T, Bai
Y, Chen Z, Chen B and Zhou M: Reversion of trichostatin A
resistance via inhibition of the Wnt signaling pathway in human
pancreatic cancer cells. Oncol Rep. 32:2015–2022. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen Z, Yang Y, Liu B, Wang B, Sun M,
Zhang L, Chen B, You H and Zhou M: Promotion of
metastasis-associated gene expression in survived PANC-1 cells
following Trichostatin a treatment. Anticancer Agents Med Chem.
15:1317–1325. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taniguchi K and Karin M: IL-6 and related
cytokines as the critical lynchpins between inflammation and
cancer. Semin Immunol. 26:54–74. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okitsu K, Kanda T, Imazeki F, Yonemitsu Y,
Ray RB, Chang C and Yokosuka O: Involvement of interleukin-6 and
androgen receptor signaling in pancreatic cancer. Genes Cancer.
1:859–867. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bharadwaj U, Marin-Muller C, Li M, Chen C
and Yao Q: Mesothelin overexpression promotes autocrine IL-6/sIL-6R
trans-signaling to stimulate pancreatic cancer cell proliferation.
Carcinogenesis. 32:1013–1024. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vera J, Rateitschak K, Lange F, Kossow C,
Wolkenhauer O and Jaster R: Systems biology of JAK-STAT signalling
in human malignancies. Prog Biophys Mol Biol. 106:426–434. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Quintás-Cardama A and Verstovsek S:
Molecular pathways: Jak/STAT pathway: Mutations, inhibitors, and
resistance. Clin Cancer Res. 19:1933–1940. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thoennissen NH, Iwanski GB, Doan NB,
Okamoto R, Lin P, Abbassi S, Song JH, Yin D, Toh M, Xie WD, et al:
Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT
pathway and potentiates antiproliferative effects of gemcitabine on
pancreatic cancer cells. Cancer Res. 69:5876–8584. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gozgit JM, Bebernitz G, Patil P, Ye M,
Parmentier J, Wu J, Su N, Wang T, Ioannidis S, Davies A, et al:
Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival
signaling in the human JAK2 V617F cell line SET-2. J Biol Chem.
283:32334–32343. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bai J, Sui J, Demirjian A, Vollmer CM Jr,
Marasco W and Callery MP: Predominant Bcl-XL knockdown disables
antiapoptotic mechanisms: tumor necrosis factor-related
apoptosis-inducing ligand-based triple chemotherapy overcomes
chemoresistance in pancreatic cancer cells in vitro. Cancer Res.
65:2344–2352. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hodge DR, Hurt EM and Farrar WL: The role
of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer.
41:2502–2512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang R, Cheng L, Xia J and Wang Z, Wu Q
and Wang Z: Gemcitabine resistance is associated with
epithelial-mesenchymal transition and induction of HIF-1α in
pancreatic cancer cells. Curr Cancer Drug Targets. 14:407–417.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen H, Guan YL, Yuan G, Zhang Q and Jing
N: A perylene derivative regulates HIF-1 alpha and Stat3 signaling
pathways. Bioorg Med Chem. 22:1496–1505. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qin A, Yu Q, Gao Y, Tan J, Huang H, Qiao Z
and Qian W: Inhibition of STAT3/cyclin D1 pathway promotes
chemotherapeutic sensitivity of colorectal caner. Biochem Biophys
Res Commun. 457:681–687. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Soto-Cruz I, Rangel-Corona R,
Valle-Mendiola A, Moreno-Morales X, Santiago-Pérez R, Weiss-Steider
B and Cáceres-Cortés JR: The tyrphostin B42 inhibits cell
proliferation and HER-2 autophosphorylation in cervical carcinoma
cell lines. Cancer Invest. 26:136–144. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu Y, Zhang J, Wu J, Zhong S and Li H:
Inhibition of JAK2 Reverses paclitaxel resistance in human ovarian
cancer cells. Int J Gynecol Cancer. 25:1557–1564. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen B, Liu Y, Zhang Y, Li J, Cheng K and
Cheng L: IL-21 is positively associated with intervertebral disc
degeneration by interaction with TNF-α through the JAK-STAT
signaling pathway. Inflammation. 40:612–622. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
American Joint Committee on Cancer (AJCC)
TNM staging system, . 2013.American Cancer Society. http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-stagingApril
5–2016
|
|
26
|
Detre S, Saclani Jotti G and Dowsett MA: A
‘quickscore’ method for immunohistochemical semiquantitation:
Validation for oestrogen receptor in breast carcinomas. J Clin
Pathol. 48:876–878. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Silvestris N, Gnoni A, Brunetti AE,
Vincenti L, Santini D, Tonini G, Merchionne F, Maiello E, Lorusso
V, Nardulli P, et al: Target therapies in pancreatic carcinoma.
Curr Med Chem. 21:948–965. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Roxburgh CS and McMillan DC: Therapeutics
targeting innate immune/inflammatory responses through the
interleukin-6/JAK/STAT signal transduction pathway in patients with
cancer. Transl Res. 167:61–66. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim BH, Yi EH and Ye SK: Signal transducer
and activator of transcription 3 as a therapeutic target for cancer
and the tumor microenvironment. Arch Pharm Res. 39:1085–1099. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bowman T, Garcia R, Turkson J and Jove R:
STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pop VV, Seicean A, Lupan I, Samasca G and
Burz CC: IL-6 roles-Molecular pathway and clinical implication in
pancreatic cancer-A systemic review. Immunol Lett. 181:45–50. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miyamoto Y, Hosotani R, Doi R, Wada M, Ida
J, Tsuji S, Kawaguchi M, Nakajima S, Kobayashi H, Masui T, et al:
Interleukin-6 inhibits radiation induced apoptosis in pancreatic
cancer cells. Anticancer Res. 21:2449–2456. 2001.PubMed/NCBI
|
|
34
|
Fofaria NM and Srivastava SK: STAT3
induces anoikis resistance, promotes cell invasion and metastatic
potential in pancreatic cancer cells. Carcinogenesis. 36:142–150.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Caceres-Cortes JR: A potent anti-carcinoma
and anti-acute myeloblastic leukemia agent, AG490. Anticancer
Agents Med Chem. 8:717–722. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nielsen M, Kaltoft K, Nordahl M, Röpke C,
Geisler C, Mustelin T, Dobson P, Svejgaard A and Odum N:
Constitutive activation of a slowly migrating isoform of Stat3 in
mycosis fungoides: Tyrphostin AG490 inhibits Stat3 activation and
growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci
USA. 94:pp. 6764–6769. 1997; View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Burdelya L, Catlett-Falcone R, Levitzki A,
Cheng F, Mora LB, Sotomayor E, Coppola D, Sun J, Sebti S, Dalton
WS, et al: Combination therapy with AG-490 and interleukin 12
achieves greater antitumor effects than either agent alone. Mol
Cancer Ther. 1:893–899. 2002.PubMed/NCBI
|
